Business News • PR NewsWire • Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting

Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting

Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting

SAN DIEGO, June 6 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests

View More : http://www.prnewswire.com/news-releases/data-from-clinical-studies-of-biotheranostics-cancertype-id-and-breast-cancer-in...

Releted News by prnewswire

Queen Meg, Registered Nurses, and Everyday Californians Greet Meg Whitman, Pete Wilson in Fresno, Sacramento areas Sunday

Academy Award Winner Sandra Bullock Makes Surprise Appearance at Spike TV's 'Guy's Choice'

NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting